Two Cancer Drug Advances Show Promise in Early Research
Early trial of Rezatapopt shows 20% response rate in advanced cancers with p53 mutations, while researchers identify AMD3100 as potential solution to enable immunotherapy in rare liver cancer.
AMD3100
DrugDrug Profile
AMD3100 is the development name for plerixafor, an immunostimulant medicine marketed as Mozobil for hematopoietic stem-cell mobilization in oncology transplantation workflows. It is used in combination mobilization settings and has regulatory approvals in major markets. The medicine is prescription-only.
- Drug Class
- Immunostimulant; CXCR4 antagonist
- Approval Status
- FDA approved for stem-cell mobilization (approved on December 15, 2008); prescription-only
- Mechanism of Action
- Antagonizes CXCR4, disrupting CXCR4/SDF-1 mediated stem-cell retention and mobilizing hematopoietic stem cells into peripheral blood
- Mozobil
- \Hematopoietic stem cell mobilization in patients with lymphoma\
- \Hematopoietic stem cell mobilization in patients with multiple myeloma\
Related News
Existing Drug May Overcome Immunotherapy Resistance in Rare Liver Cancer
Study finds FDA-approved drug AMD3100 can mobilize immune T cells to attack fibrolamellar carcinoma, a rare liver cancer affecting children and young adults that has resisted immunotherapy treatment.
FDA-Approved Drug AMD3100 May Enable Immunotherapy for Rare Liver Cancer
Researchers find that AMD3100, an existing FDA-approved drug, can reverse T-cell exclusion in fibrolamellar carcinoma, potentially allowing immunotherapy to fight the rare and fatal liver cancer that primarily affects children and young adults.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04058145 |
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma |
WITHDRAWN | PHASE2 |
| NCT04045821 |
Endometrial Rejuvenation Study |
TERMINATED | NA |
| NCT01655875 |
AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia |
TERMINATED | PHASE1 |
| NCT01026987 |
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant |
COMPLETED | PHASE1 |
| NCT00914849 |
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies |
COMPLETED | PHASE2 |
| NCT00733824 |
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma |
COMPLETED | PHASE1/PHASE2 |
| NCT00512252 |
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia |
COMPLETED | PHASE1/PHASE2 |
| NCT00479115 |
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 |
COMPLETED | PHASE1/PHASE2 |
| NCT00396968 |
AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS |
WITHDRAWN | PHASE1/PHASE2 |
| NCT00322127 |
An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers |
COMPLETED | PHASE1 |